Mimedx Group earnings were $40.8M for the trailing 12 months ending Sep 30, 2025, with -55.6% growth year over year. The latest MDXG earnings report on Sep 30, 2025 announced Q3 2025 earnings of $16.7M, up 74.1% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, MDXG reported annual earnings of $42.4M, with -27.2% growth.
MDXG past earnings growth
How has MDXG's earnings growth performed historically?
On MDXG's earnings call on Invalid Date, Mimedx Group (NASDAQ: MDXG) reported Q3 2025 earnings per share (EPS) of $0.11, up 120% year over year. Total MDXG earnings for the quarter were $16.75 million. In the same quarter last year, Mimedx Group's earnings per share (EPS) was $0.05.
As of the last Mimedx Group earnings report, Mimedx Group is currently profitable. Mimedx Group's net profit (also called net income) for the twelve months ending Sep 30, 2025 was $40.83 million, a 53.85% decrease year over year.
What was MDXG's earnings growth in the past year?
As of Mimedx Group's earnings date in Invalid Date, Mimedx Group's earnings has grown -55.56% year over year. This is 118.8 percentage points lower than the US Biotechnology industry earnings growth rate of 63.25%. MDXG earnings in the past year totalled $40.83 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.